SciELO - Scientific Electronic Library Online

 
vol.42 issue2Effects of therapeutic plasma exchange on liver function test and coagulation parameters in acute liver failure patients author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

Share


Hematology, Transfusion and Cell Therapy

Print version ISSN 2531-1379On-line version ISSN 2531-1387

Abstract

CRUSOE, Edvan De Queiroz et al. Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation. Hematol., Transfus. Cell Ther. [online]. 2020, vol.42, n.2, pp.118-124.  Epub July 24, 2020. ISSN 2531-1387.  https://doi.org/10.1016/j.htct.2019.05.004.

Background:

The treatment of multiple myeloma (MM) has evolved significantly in the past decade, and new drug combinations have improved the response rates and prolonged survival. Studies comparing different induction chemotherapy regimens have shown that triple combinations have better results than double combinations. However, comparisons among different triple combinations are rare in the literature.

Methods:

We retrospectively compared two triple combinations comprising bortezomib, cyclophosphamide and dexamethasone (VCD) versus thalidomide, cyclophosphamide and dexamethasone (CTD), and aimed at identifying which of the two combinations would yield better response rates following four induction cycles prior to hematopoietic cell transplantation in patients with untreated multiple myeloma.

Results:

We retrospectively reviewed the medical records of 311 patients from 24 different centers.The VCD regimen was used as induction therapy by 117 (37.6%) patients, whereas 194 (62.4%) patients received the CTD regimen. After four cycles of induction on an intention-to-treat basis, 54% of the patients in the VCD group achieved at least very good partial response versus 42.8% in the CTD group (p = 0.05). We observed no difference in neuropathy or thrombotic events rates among the two regimens.

Conclusion:

Our results corroborate the superiority of the triple combination regimes containing bortezomib over the triple combination with thalidomide as pre ASCT induction therapy in MM.

Keywords : Antineoplastic combined chemotherapy protocols; Bone marrow transplantation; Bortezomib; Multiple myeloma; Thalidomide.

        · text in English     · English ( pdf )